.svg){kind=small}
12th-14th November Tokyo Big SightRichmond Pharmacology is attending the DIA in Tokyo 2017: Toward Valuable Medicine Developments for Patients - Expectations for the Future through Effective Utilization of Artificial Intelligence and Big Data. Dr Taubel will presenting his latest scientific poster presentation - Integration of ICH E14 Cardiac Safety in Phase I studies and Validation of Exposure-QTc Relationships.
View More Program Information Here:http://www.diaglobal.org/Tools/Content.aspx?type=eopdf&file=%2fproductfiles%2f6371290%2f17303%2E.pdf
-min.jpg)
.jpg)
Latest news
Richmond Appoints Lisa Campbell as Director of Regulatory Strategy
April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read moreVon Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol
April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read moreEvents
Swiss Biotech Day 2025
5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event
